MAPK6 (Mitogen-Activated Protein Kinase 6), also known as ERK3 (Extracellular Signal-Regulated Kinase 3), is an atypical member of the MAP kinase family. Unlike classical MAP kinases such as ERK1/2, MAPK6 has distinct regulatory mechanisms and cellular functions. It plays critical roles in cell division, differentiation, stress responses, and synaptic plasticity. In the nervous system, MAPK6 is involved in neurodevelopment, learning and memory, and has been increasingly recognized for its contributions to neurodegenerative processes. This page provides comprehensive coverage of MAPK6's molecular function, disease associations, expression patterns, and its emerging role in Alzheimer's disease (AD), Parkinson's disease, and related neurodegenerative disorders.
MAPK6 is a serine/threonine protein kinase that functions as part of the MAP kinase signaling cascade. While it shares structural homology with other MAP kinases, MAPK6 exhibits unique features including its lack of classical activation loop phosphorylation sites and its regulation through nuclear-cytoplasmic shuttling. Research over the past two decades has revealed that MAPK6 is involved in diverse cellular processes beyond its initially characterized roles in cell cycle progression, including neuronal differentiation, synaptic plasticity, and stress response pathways. The kinase has emerged as a potential therapeutic target in neurodegeneration due to its regulation of key processes including tau phosphorylation, neuroinflammation, and neuronal survival.
MAPK6 (ERK3) is an atypical MAP kinase involved in cell division, differentiation, stress responses, and synaptic plasticity. It plays critical roles in neurodevelopment and has been increasingly recognized for its contributions to neurodegenerative processes.
| Gene Symbol | MAPK6 |
|---|---|
| Full Name | Mitogen-Activated Protein Kinase 6 |
| Alternative Names | ERK3, PRKM6 |
| Chromosomal Location | 15q21.2 |
| NCBI Gene ID | [5603](https://www.ncbi.nlm.nih.gov/gene/5603) |
| OMIM | [616431](https://www.omim.org/entry/616431) |
| Ensembl ID | [ENSG00000170048](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000170048) |
| UniProt | [Q9Y4G2](https://www.uniprot.org/uniprot/Q9Y4G2) |
| Protein Length | 721 amino acids |
| Protein Kinase Domain | Serine/Threonine protein kinase, MAPK family |
| Associated Diseases | Alzheimer's disease, Parkinson's disease, neurodevelopmental disorders, cancer |
MAPK6 encodes mitogen-activated protein kinase 6, an atypical member of the MAP kinase family. Unlike classical MAP kinases, MAPK6 is regulated primarily through interactions with MAPKAP kinases (MK2/MK3) rather than through dual phosphorylation of the activation loop. MAPK6 participates in diverse signaling pathways controlling cell proliferation, differentiation, stress responses, and synaptic plasticity. In the brain, MAPK6 is expressed in neurons and glial cells where it modulates neuronal development, cognitive function, and responses to neurotoxic stress. Dysregulation of MAPK6 signaling has been implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions, making it a subject of ongoing research interest.
MAPK6 is a serine/threonine protein kinase that catalyzes the transfer of phosphate groups from ATP to serine or threonine residues on substrate proteins. The canonical kinase domain of MAPK6 spans residues 46-330 and contains the characteristic motifs required for ATP binding and catalysis. Unlike classical MAP kinases such as ERK1/2, MAPK6 lacks the TXY activation motif in its activation loop; instead, it is constitutively active as a kinase and is regulated primarily through:
The primary downstream targets of MAPK6 are MAPKAP kinase 2 (MK2, also known as MAPKAPK2) and MAPKAP kinase 3 (MK3). The MAPK6-MK2/3 module regulates:
MAPK6 phosphorylates several known substrates:
The substrate recognition by MAPK6 is mediated through specific docking interactions, and the biological outcomes depend on the cellular context and the complement of expressed substrates.
MAPK6 occupies a unique position in the MAP kinase signaling network. While it can be activated by certain extracellular stimuli, it is not typically integrated into the classic RAS-RAF-MEK-ERK1/2 cascade. Instead, MAPK6:
In neurons, MAPK6 interfaces with several pathways implicated in neurodegeneration:
MAPK6 exhibits a broad expression pattern across tissues, with particularly high levels in the brain:
Highest expression is observed in brain, with moderate levels in:
MAPK6 is predominantly cytoplasmic but undergoes nuclear-cytoplasmic shuttling. In unstimulated cells, it is distributed throughout the cytoplasm. Upon certain stimuli or stress, MAPK6 can translocate to the nucleus where it may phosphorylate nuclear substrates.
Multiple lines of evidence link MAPK6 to Alzheimer's disease pathogenesis:
Tau pathology: MAPK6 phosphorylates tau at specific serine residues, and this phosphorylation is detected in Alzheimer's disease brain. The kinases that modify tau are key players in NFT formation.
Amyloid-beta effects: Amyloid-beta (Aβ) treatment of neurons leads to altered MAPK6 signaling, suggesting it may be involved in the cellular response to Aβ toxicity.
Synaptic dysfunction: MAPK6 is implicated in synaptic plasticity mechanisms that are disrupted in AD, including long-term potentiation (LTP).
Neuroinflammation: MAPK6 signaling influences the inflammatory response in AD, potentially modulating microglial activation and cytokine production.
In Parkinson's disease context:
Alpha-synuclein phosphorylation: MAPK6 may contribute to phosphorylation of alpha-synuclein at serine129, a modification associated with Lewy body formation.
Mitochondrial dysfunction: MAPK6 signaling intersects with pathways controlling mitochondrial quality control, relevant to PD pathogenesis.
Dopaminergic neuron survival: The kinase modulates survival signaling in dopaminergic neurons, the population lost in PD.
Neuroinflammation: Similar to AD, MAPK6 influences glial responses relevant to PD progression.
| Interaction Partner | Relationship | Functional Significance |
|---|---|---|
| MAPKAPK2 (MK2) | Substrate/activator | Primary downstream kinase in signaling module |
| MAPKAPK3 (MK3) | Substrate/activator | Secondary downstream kinase |
| HSP90AA1 | Co-chaperone | Required for MAPK6 stability and function |
| 14-3-3 proteins | Binding partner | Regulates subcellular localization |
| Cyclin-dependent kinases | Cross-talk | Cell cycle regulation |
| p38 MAPK | Parallel pathway | Stress response signaling |
| AKT1 | Cross-talk | Survival signaling modulation |
MAPK6 structure and catalysis: Structural studies have revealed the molecular basis for MAPK6's atypical regulation and its interactions with MAPKAP kinases.
Neurological disease associations: Genomic studies have identified associations between MAPK6 variants and neurodevelopmental and neurodegenerative conditions.
Therapeutic targeting: Small molecule inhibitors of MAPK6 have been developed and tested in preclinical models of neurodegeneration.
Animal models: Knockout and transgenic mouse models have illuminated the in vivo functions of MAPK6 in the nervous system.
Zebrafish have been used to study MAPK6 function in neural development, revealing requirements for proper brain morphogenesis and neuronal differentiation.
While MAPK6 is not a high-penetrance disease gene for monogenic neurodegeneration, polymorphisms in the MAPK6 gene have been associated with:
MAPK6 represents a potential therapeutic target for neurodegeneration: